Q3 2024 Dare Bioscience Inc Earnings Call

MarDee Haring-Layton

Thanks, Sabrina, and thanks, everyone, for joining us today. I would now like to summarize Daré’s financial results for the quarter ended September 30, 2024, which I will refer to as the third quarter. As Sabrina mentioned, Daré’s business strategy is to assemble and advance a portfolio of differentiated product candidates that address meaningful unmet needs we’ve identified in women’s health, and then to monetize the value of our portfolio’s clinical and regulatory advances over the near and long term.
The investment required to build and advance the portfolio includes corporate overhead, portfolio acquisition and maintenance costs, and ongoing research and development or R&D expenses. During the third quarter of 2024, our general and administrative expenses were approximately $2 million, which is a 24% increase compared to Q3 — I’m sorry, decrease, compared to Q3 2023, due primarily to reduced professional services expenses and reduced commercial readiness expenses.
Our R&D expenses, which vary from period to period based on clinical, preclinical, manufacturing, regulatory and other activities across our entire portfolio, were approximately $2.7 million for the third quarter, which is a 60% decrease compared to Q3 2023. As we guided previously this year, we continue to anticipate our full year 2024 R&D expenses will be less than our 2023 R&D expenses.
Our comprehensive loss for the third quarter was approximately $4.7 million. We ended the third quarter with approximately $11.2 million in cash and cash equivalents and had approximately 8.7 million shares of common stock outstanding as of November 13. In October, we entered into an equity line arrangement with Lincoln Park, pursuant to which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $15 million of our common stock.
Such sales of common stock, if any, will be subject to certain limitations that may occur from time to time at our sole discretion over the 24-month period commencing on the date that a registration statement covering the resale by Lincoln Park of shares that have been and may be issued under our purchase agreement is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions in the purchase agreement are satisfied.
In October, we also entered into a sub-award agreement with a consortium management firm under which we are entitled to receive funding of up to $10 million in milestone-based payments subject to our achievement over an approximately 24-month period of specified research activities and objectives relating to the advancement of our DARE-HPV development program, including commencement of a Phase 2 clinical study to evaluate the safety and preliminary efficacy of DARE-HPV for the clearance of high-risk HPV infection in women.
The sub-award agreement was the result of our selection by ARPA-H, an agency within the US Department of Health and Human Services, as an awardee of ARPA-H’s Sprint for Women’s Health, which was announced by First Lady Jill Biden in February 2024 and is the first major deliverable of the White House Initiative on Women’s Health Research.
In addition, as Sabrina mentioned, and I will share more about later, we announced yesterday that we entered into a grant agreement with the foundation for a grant of up to approximately $10.7 million, approximately $5.4 million of which we expect to receive this year, to fund activities related to the identification and development of a novel nonhormonal intravaginal contraceptive product candidate, and to add additional clinical study sites intended to accelerate the ongoing Ovaprene pivotal study.
These nondilutive funding agreements represent our commitment to being creative, collaborative and opportunistic in seeking the capital needed to meet our objectives and to build shareholder value. We encourage investors to review the more detailed discussion of our financials, our financial condition, liquidity, capital resources and risk factors in our Form 10-Q for the quarter ended September 30, 2024, which we filed this afternoon, as well as our annual Form 10-K for the year ended December 31, 2023, which was filed on March 28, 2024.
I would now like to turn the call back over to Sabrina.

Sabrina Johnson

Thanks, MarDee. I’m now going to talk through our 2024 accomplishments to date and, importantly, with some perspective on how those frame anticipated milestones. And with a focus, as I mentioned upfront, on the late-stage candidates, Sildenafil Cream and Ovaprene. But first, I do want to provide an update on our on-market asset, XACIATO. So as a reminder, XACIATO, our clindamycin phosphate 2% vaginal gel, is the first FDA-approved product to emerge from our portfolio.
It’s indicated, as I mentioned upfront, for the treatment of bacterial vaginosis in female 12 years of age and older. As you may recall, it’s a colorless single-dose vaginal gel that can be applied at any time of day. And it’s formulated with the goal of limiting leakage and increasing vaginal retention time, known as time spent in place. And in the first quarter of this year, of 2024, through our commercialization agreement with Organon, XACIATO became available by prescription across the United States. We’ve been pleased with Organon’s progress in this first year of launch.
As of October, the Organon women’s health sales team continued to see steady month-over-month increases in total prescriptions of XACIATO, in line with the opportunity for a new branded entrant in the category. And the team continues to work towards novel go-to-market fulfillment options and enhancements to ensure a friction-less experience for both patients and providers.
And Organon’s access team continues to build on the successful coverage achieved at launch through additional wins. For example, they had a recent addition to the Preferred Drug List for Texas Medicaid, with no prior auths or step-edits required. And that provides access to an additional 4.1 million patients.
And Organon’s women’s health sales team remains focused on providing XACIATO’s strong clinical value proposition to clinicians who treat bacterial vaginosis and who continue to affirm their belief that unmet needs exist in this therapeutic area. I’ll now turn to Sildenafil Cream.
As I mentioned upfront, we have continued our constructive interactions with the FDA on the development program for Sildenafil Cream as a treatment for female sexual arousal disorder, including, importantly, with respect to the proposed efficacy endpoints to take forward into Phase 3 development.
As we’ve mentioned several times, this would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. We look forward to providing updates on the FDA’s feedback, the Phase 3 study designs and plans, as well as any relevant updates on our collaboration strategy as they become available.
In the meantime, we have been making operational progress towards that planned Phase 3 study. As you know, there are currently no FDA-approved treatments for any form of sexual arousal disorder in women, meaning Sildenafil Cream has the potential to be the first.
And sildenafil is the active ingredient in tablet form for oral administration, currently marketed under the brand name Viagra, for the treatment of erectile dysfunction in men. And I don’t need to remind you, that was undoubtedly one of the most successful prescription products ever launched. And market research suggests that approximately 20 million women in the US
experience symptoms of low or no sexual arousal. So we look forward to providing additional updates on the development program as they are available. In terms of Ovaprene, wanted to provide an update on the advancement of the Phase 3 study of Ovaprene, which is our novel investigational hormone-free monthly intravaginal contraceptive. And the commercial rights for the US are under a license agreement with Bayer.
So nonhormonal contraception represents a significant commercial market opportunity. And there are currently no monthly hormone-free contraceptives approved by the FDA. So Ovaprene has the potential to be a disruptive product in the contraceptive category and an important option for women who cannot use hormone-based birth control products or prefer not to do so. Based on market research, approximately 35 million women in the US alone are potential candidates for Ovaprene.
Working with study collaborators at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, of the National Institutes of Health, or NIH, and our commercial collaborator, Bayer, we commenced the patient enrollment in the Ovaprene pivotal Phase 3 clinical study in December 2023. And as you may recall, women are followed over 13 cycles or 12 months of Ovaprene use.
Recruitment is currently proceeding at a little more than 10 sites across the United States, and that’s supported by a central advertising campaign for the study that launched in March of this year. As we discussed last quarter, that particular subset of the total sub-study sites that are ongoing in the trial have been the most successful in translating into study participants. Considerable interest we continue to see from women in response to the central advertising campaign.
So based on the current average enrollment rate, we anticipate that approximately half of our target number of participants to complete the study, or 125 women, will complete approximately six months of product use, which is half of the full 12 months, by the end of the second quarter of 2025.
With the grant funds we expect to receive this year under the grant agreement we just announced yesterday, we’re going to add additional study sites, and we expect that to accelerate the study. Based on the communications to date with the FDA, if successful, we believe that just the single registration study would be required to support a premarket approval application submission with the FDA.
So now onto the DARE-HPV program. We mentioned at the start of the call and MarDee mentioned our announcement of the $10 million award that we were selected to receive for DARE-HPV. As I mentioned, it’s an innovative investigational treatment for HPV-related cervical diseases. And I can’t stress enough that essentially all cervical cancer cases worldwide are caused by HPV infection.
And unfortunately, despite the advancements in HPV screening and vaccination, which are fantastic, in the United States, an estimated 100,000 women are still treated for cervical precancer each year. And even more unsettling, an estimated 4,000 women will die from cervical cancer in 2024. Today, cervical precancers are monitored until they reach the last stage, since the most common treatment is surgery, which removes part of the cervix.
And that surgery is associated with an increased risk of preterm birth and sexual dysfunction, and therefore is not recommended for patients with fertility concerns. In the US, about 10% of women with HPV infection on their cervix will develop long-lasting HPV infection that puts them at risk for cervical cancer.
So DARE-HPV has the potential to be the first FDA-approved pharmaceutical intervention that could treat both late-stage cervical lesions as well as earlier-stage HPV-related cervical infections. And that could really change the paradigm around how HPV-related cervical diseases are clinically managed today. Their HPV is reflective of the type of development program we like to advance at Daré.
It’s first-in-category, but it leverages active pharmaceutical ingredients that have been approved to treat other viral infections, so they’re well known and understood. Specifically, DARE-HPV is an investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, with the potential, as I mentioned, to be very first-in-category treatment for HPV-related cervical diseases.
We look forward to conducting activities necessary to enable submission of an IND application to the FDA for a Phase 2 randomized placebo-controlled, double-blind clinical study of DARE-HPV for clearance of high-risk HPV infection in women. And all of that will be supported with the funding we received as an ARPA-H Sprint for Women’s Health $10 million awardee. We also wanted to provide updates on 2 of our other first-in-category product opportunities.
DARE-VVA1 is our proprietary formulation of tamoxifen for intravaginal administration. And it’s being developed as a hormone-free alternative to estrogen-based therapies for the treatment of moderate to severe dyspareunia, which is pain during sexual intercourse. And we’re conducting activities in preparation for a Phase 2 clinical trial of DARE-VVA1 based on our FDA-cleared IND for that use.
And DARE-PTB1, as I mentioned upfront, that’s our intravaginal ring designed to deliver bioidentical progesterone continuously over 14 days for the prevention of preterm birth. We’re conducting activities necessary to enable submission of an IND application to the FDA for a Phase 1 clinical study.
And that’s supported by a $2 million grant from NICHD. That Phase 1 study will also serve to support safety and PK for this progesterone intervaginal ring to also be investigated for luteal phase support as part of an IVF regimen.
And finally, I did want to share a little bit more about the grant we just announced from the Bill & Melinda Gates Foundation. In addition to the important support for the Ovaprene clinical trial, the grant will also support activities to derisk the development of a novel nonhormonal intravaginal contraceptive that could be suitable for women and acceptable for women in low- and middle-income country settings who need or prefer such a product to avoid an unplanned pregnancy.
We believe that we’re the right organization to move innovations like these programs forward given our extensive experience in the contraceptive space, in particular, with novel nonhormonal product development, and our proven ability to advance development of differentiated product candidates that fulfill unmet needs in women’s health.
So we’ll receive, as MarDee outlined, an initial payment of approximately $5.4 million under the grant agreement in 2024. And then additional payments, as is typical, are contingent upon our achievement of certain development and reporting milestones specified in the grant agreement during the approximately 24-month period term of that grant agreement. So similar to the ARPA-H award, which is also a 24-month period, for that $10 million disbursement, this $10.7 million disbursement is also over a 24-month period.
So in summary, we continue to progress our portfolio of potential first-in-category product candidates, and look forward to providing more updates as we work to advance some of the most potentially disruptive candidates for the health and well-being of women in decades, collaborating with leading companies, including Organon for XACIATO and Bayer for Ovaprene, as well as funding agencies, to commercialize and deliver these treatments to as many women as possible.
I’d now like to turn the call over to the operator for Q&A.

Operator

Thank you, Sabrina. (Operator Instructions) Catherine Novack, Jones trading.

Catherine Novack

Hi. Good afternoon. Congrats on all the progress. Congrats especially on being able to expand or accelerate enrollment in the Ovaprene study. I just wanted to touch on the potential interim — or the potential interim look by the end of 2Q ’25. Is this something we’re still expecting? And then what should we be looking for from this interim readout? Just safety? Or how much efficacy can we learn from an interim read?

Sabrina Johnson

Yeah, Catherine, that’s a great question. So thanks for asking. And first of all, thank you for the congratulations on the nondilutive funding we got. It’s a really nice addition to be able to add some sites — additional sites to the study.
And we’re really excited to do that. Right now all of the sites are through the NICHD’s Clinical Trial Contraceptive Network. So it’s going to be really great to be able to add some additional sites to give them experience as well, right, with the product outside of that, and the opportunity to go even faster with the program.
So we’re thrilled about that. In terms of getting partway through that important enrollment milestone and having that critical halfway mark in terms of subjects and time in the study, it’s definitely an important place for us to look at the data.
As people may or may not recall, this is open label, that’s standard for any contraceptive trial, in that everyone in the study, just for ethical reasons, right, they’re all getting active product. There’s no placebo control. And that does create interesting opportunities like this to continue to look at safety, we do have a data safety monitoring board, as well as other considerations throughout the course of the study, evaluating it.
In terms of exactly what information will be reviewed at that time and what may be made publicly available and how that will be handled, that’s really something that we are working closely with our commercialization collaborator, with Bayer, on as well as we think this through, as well as, obviously, the data safety monitoring board and charter for the program. And the reason I say that is that this is a 12-month or 13-cycle ultimate contraceptive study.
And there’s a lot of data to indicate that contraceptive rates just get better, right, over time. So that’s one of the things we’re going to have to think about in terms of what we look at and how any disclosure would be handled around that. So more to come on that. It’s an active and ongoing discussion with our commercialization collaborator, Bayer. So we will give more updates on that as we get closer.

Catherine Novack

Great. And then just one more, on sildenafil. Can you share a little bit more about what you mean by operational progress towards Phase 3? And if you can let us know what’s still outstanding when it comes to your FDA interaction. Do you need additional information? Or are you — do they have anything else that they need from you in order to move this along?

Sabrina Johnson

Yeah, More great question. So first of all, what I mean in terms of operational progress is — taking a step back, and actually going to the second part of your question around discussions with the FDA. Really our discussions with the FDA have, importantly, very much been focused on — at the end of Phase 2, they’re always focused on big picture, right? What all do we need for the NDA submission?
Of course. That’s an important part of end of Phase 2. But in a circumstance like this when you’re pursuing development of a first-in-category product for which the first-in-category fantastic opportunity is because no one has done this before, and so a lot of the focus is really on what should be the appropriate endpoints, right, for a Phase 3 program, what’s important to monitor, what’s important to demonstrate. So really that’s then a lot of the focus of the conversation. And what does that Phase 3 program look like, right?
What are the expectations in terms of efficacy and safety from that Phase 3 program? And we’ve shared before that the expectation is two Phase 3 trials to support registration. But the detail around what exactly does that entail and what’s going to be required, so that’s really where the focus has been.
And the Phase 2 data is so rich. It was a learning experience for everyone in terms of the patient population, the endpoints, where they see improvement, where they want to see improvement.
And so it’s really just going through all that. So frankly, more than anything, it’s just time. And these interactions, it’s not likely that get to just call the FDA every day and have a conversation. So it’s very processed in terms of how communication goes back and forth. So it’s really just going through that, answering questions, getting feedback, and aligning.
But as I said upfront, it’s been very constructive. We’ve been very pleased with how constructive the FDA has been in collaborating with us and wanting very much to also get us to the place where we can be ready to go, but making sure they understand how important it is to us and our shareholders that there’s great alignment on the expectations for Phase 3.
So that’s where we’re really trying to ensure, importantly, around expectations for success, so that we can clearly communicate those and we all know what we’re working towards. In terms of then operational readiness, it’s really around making sure that, as soon as we reach that alignment, we’re ready to go.
So ready to go in the things that we can control, such as making sure CRO that we want to work with, making sure we know the sites that we want to work with, making sure that we have drug supply so that we’re not waiting to manufacture something.
So those are all the things, right, that are completely within our control and that we’ve been doing to make sure that we are operationally ready such that all we’re waiting for is having that Phase 3 protocol that we know everyone is aligned on, so that we can then initiate the process to go.
Obviously, we always have to think about financial considerations, which is also why we’ve tried to make sure that we’re ready for that as well in terms of some of the structures that MarDee talked about that we’ve put in place.

Catherine Novack

Got it. That makes sense. Definitely looking forward to hearing some of those updates when you’re able to share them. Thanks, again, for taking my questions. Congrats on all the progress.

Sabrina Johnson

Thank you.

Operator

Douglas Tsao, H.C. Wainwright.

Sabrina Johnson

Hello?

Operator

Mr. Douglas Tsao, I think your microphone is on mute.
Kemp Dolliver, Brookline Capital Markets.

Brian Kemp Dolliver

Thank you. I’m definitely not on mute. So a couple of questions, if I may. With the Ovaprene trial and this potential interim look, you obviously wouldn’t be at a point where you would stop the trial early. So what specific actions might follow from doing that analysis?

Sabrina Johnson

Yeah, it’s a great question. So what the DSM is charged with is really obviously monitoring safety. So that’s routine. And this is a great question, that’s why there’s obviously been discussion around it. One can look as it’s open label.
So one can take a look. Obviously, you don’t — there’s no value in doing that until you’ve got — you’re far enough in the study to have enough patients and cycles in order to look at anything, frankly, safety or efficacy perspective. And so there isn’t anything specific beyond that that I can say at this time. It’s one of those situations where one can. And the reason that time point is also important is it is the partway through, right, the study.
And there really, there isn’t any contraceptive product, at least to my knowledge, that’s ever been studied for less than that time period, right? You need a certain number of cycles and six months, at least, looking at these methods. And so that’s why that time point for us has been something we’ve thought about, and when are we going to be there, right. It’s an important milestone. I wish I had a clearer question for you.
Like I said upfront, there are things that we have to think about in terms of what we look at then and what we do with that information given what we know very well in the literature about contraceptive studies and how there can be changes in the Pearl Index between 6 and 13 months.
Always getting better over that time frame. So that does raise considerations, and particularly also for our commercialization partner, Bayer. So more to follow as we get closer. Importantly, we obviously will be doing our DSM safety assessments and that’s also an important one at that point as well.

Brian Kemp Dolliver

Okay. That’s great. And just stay on that particular trial for the moment. So you have 10 sites now. You’re going to have some additional funding available. How many additional sites do you intend to add?

Sabrina Johnson

Yeah, that’s a great question. And just to be clear too, we have — there’s 20 total sites under the Clinical Trial Contraceptive Network under the NIH. And all of those sites have been involved in the study and obviously would have active patients that are continuing to be followed.
We are focusing now recruitment efforts on a little more than half, so a little more than 10, of those sites that, as I mentioned on the August call and reiterated today, have really been quite exceptional in terms of how they translate the interest from the patients, from women, in the study into study participants. So we want to be thoughtful with the resources that we have together under our collaborative research agreement with the NIH that really covers those sites in the study.
And so that’s why as we think about forward-looking recruitment, we’re really focused on that 10-plus sites through that CCTN group of sites. The additional funding will likely allow us to add a handful of sites to the study which, for a study of this size and just given how many sites we’ve had and how many have been really are active, really efficient enrollers that can have a meaningful impact.
So that’s why we’re super excited about being able to do it. And it allows us to add sites that are outside of the CCTN network. We’ve been honored and really happy to be working with the CCTN network, the clinical — Contraceptive Clinical Trial Network that works so closely with the NIH.
But we’ve also had fantastic experience with community-based sites that have worked with us on all of our other studies. They were in our XACIATO study, they’ve been in our sildenafil study. So we’re also very excited to get a chance to work with some of them on Ovaprene as well because they’ve been very anxious to do so.

Brian Kemp Dolliver

Great. And my last question relates to sildenafil and just to think about the potential timeframe once you get FDA alignment and deal with the operational requirements, and certainly having funding. So if we just think of funding as being the most gating factor here, if you were to get funding, say, next month, how soon do you think you’d be able to initiate the trial?

Sabrina Johnson

Yeah, another great question. I mean really if you think about study start-up, we’ve done as much as we can upfront, but there’s still operational things that take not days, but weeks, and some of them several weeks, around contracting the sites, things we can’t do even though we know who we want to work with, you can’t do until you have the final protocol, going through IRB.
So those are those things that we’ll go as fast as we can. But there is traditional study startup that some of those things we cannot do until we have the final protocol. So that, to your point, on protocol and funding, then it’s just those traditional study startup activities that can often take a couple to a few months, realistically, with site initiations as well.

Brian Kemp Dolliver

So a start next year is possible?

Sabrina Johnson

Absolutely. Yes. Absolutely. Yeah. Once we get that final protocol aligned with the FDA, then yes, then it’s down to, your point, obviously, always have to think about the money, importantly. But then it’s really just that operational study startup, things like the IRB, site contracts, and the site initiations.

Brian Kemp Dolliver

Great. Thank you.

Sabrina Johnson

Thanks.

Operator

Douglas Tsao, H.C. Wainwright.

Douglas Tsao

Hi. Good afternoon. Can you hear me this time?

Sabrina Johnson

Yes. Yes.

Douglas Tsao

Thank you. Okay. Sabrina, I’m just curious in terms of the Ovaprene study and the addition of these new sites. How quickly do you anticipate them being able to enroll study in the trial? And ultimately, do you have a sense of what percentage of the total enrollment might come from these sites? And will there be different types of patients that will be added by going outside of the CCTN network?

Sabrina Johnson

Yeah, more great question. So as I alluded to in the last question from Kemp, these are sites that we’ve identified that we would like to add to the study, are sites that we’ve had great experiences with in the past and have a nice track record with.
Some of them have done both our bacterial vaginosis study as well as the sildenafil study. Some of them just did one of those studies. But what that translates into is like we’ve contracted with them before, we’ve worked with them before.
So we — there are going to be efficiencies that would be very different than if we were going out to like brand-new sites that we don’t know. So our expectation is that, again, this is still, it’s weeks, right? It’s not days, it’s weeks, to get through this process.
But our expectation is we’re going to work really quickly to get those sites up and going as quickly as possible, up and going as quick as possible in the new year, right? We’re going to use this time now through the end of the year to work quickly with them, and we know who they are that we want to work with.
And in terms of your also great question around: is it going to bring into the study different types of subjects? We’re also always looking at demographics as well, in terms of the women that are enrolling in the study. And we do want to ensure we are hitting some diversity objectives in different parts of the country as well that we’re allowing to participate in the study.
So it also does give us some additional, I think, opportunity in that regard as well that we want to be very thoughtful about and leveraging. And then in terms of what proportion of the subjects could they contribute to the study, these are, again, these are sites that have performed very well for us historically in terms of translating, like in the sildenafil study, translating again interest into participants.
And that’s not trivial by the way. And the Clinical Trial Contraceptive Network sites have been great, and just some of them are better at that than others for this particular study. And so that’s what it’s going to come down to, is how the interest is there.
And we’re selecting sites that have shown us in the past can be very — including in past contraceptive studies that they’ve run, can be very efficient in translating someone who’s interested and meets the eligibility criteria for the study into a study participant. And if they do that well, they can make a meaningful — we’re not so far along in the study that they can’t make a meaningful contribution.
They can still make a meaningful contribution to the study participants. And we think that would be great in terms of also just overall diversity in the study, and diversity of sites.

Douglas Tsao

That’s helpful. And Sabrina, you did mention the amount of funding that would be needed to — for the — to complete the Sildenafil Cream program. I’m just curious about how — some thoughts on how much of that you need upfront to begin the program?

Sabrina Johnson

Yeah, I mean this is the — I would say, a particular study, an individual study, we’re estimating, based on all the conversations we’ve been having with the FDA and as well as the CRO, it’s about $15 million of direct external costs related to each of the study. So that’s $30 million in total if you add the two together. So certainly there’s not an expectation that we would want to make sure we had $30 million before we started. But a particular trial is $15 million, and so 15 is an important number for us to think about.
Now having said that, this is not — obviously, it’s not a life-threatening condition. And it’s — the expectation is it’s going to be a fairly — it’s a shorter study period for the women who are participating. So there you can be creative around that in terms of how much you literally need upfront before you start because it’s just a short period of time, you can keep enrolling and completing, right, people. So those are all things we’re going to look at at the time. But I think the important thing is to understand that we don’t need $30 million.
But an individual study is $15 million and we’d want to make sure we feel very confident, even if not all of that is there upfront, that we feel very confident that we’re going to be able to continue the women through the study.

Douglas Tsao

Okay. Great. Thank you so much. That’s helpful.

Sabrina Johnson

Yeah.

Operator

That concludes the question-and-answer session. I would like to turn the call back over to Sabrina Martucci Johnson for any additional or closing remarks.

Sabrina Johnson

Thanks. Well, thank you all for taking the time this afternoon to hear about our recent updates and our ongoing commitment to drive value for all of Daré’s stakeholders by identifying and advancing potential new therapies to provide additional choices, enhance outcome, and ease of use for women.
As you heard today, we continue to make great progress. And with our unique model, including being able to leverage a lot of nondilutive funding that we just brought in over the last month, and the support of our commercial collaborators, we believe we’re well positioned to accelerate innovation for women everywhere, while also driving value for all of Daré stakeholders. So we look forward to keeping you updated on our progress and we thank you for listening today.

Operator

Ladies and gentlemen, this concludes today’s conference call. You may now disconnect.